https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AInsulin_analog%2F4%2FenTranslations:Insulin analog/4/en - Revision history2026-08-18T08:09:37ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_analog/4/en&diff=130140&oldid=prevFuzzyBot: Importing a new version from external source2024-03-19T08:49:43Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>===Lispro===<br />
{{main|Insulin lispro}}<br />
[[Eli Lilly and Company]] developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through [[recombinant DNA]] technology so that the penultimate [[lysine]] and [[proline]] residues on the C-terminal end of the B-chain were reversed. This modification did not alter the insulin receptor binding, but blocked the formation of insulin [[protein dimer|dimer]]s and hexamers. This allowed larger amounts of active monomeric insulin to be available for [[postprandial]] (after meal) injections.</div>FuzzyBot